DK1694360T3 - Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning - Google Patents

Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning

Info

Publication number
DK1694360T3
DK1694360T3 DK04810420.2T DK04810420T DK1694360T3 DK 1694360 T3 DK1694360 T3 DK 1694360T3 DK 04810420 T DK04810420 T DK 04810420T DK 1694360 T3 DK1694360 T3 DK 1694360T3
Authority
DK
Denmark
Prior art keywords
antagonist anti
dosing regimen
antibodies
inflammatory diseases
transplant rejection
Prior art date
Application number
DK04810420.2T
Other languages
English (en)
Inventor
Li Long
Mohammad Luqman
Asha Yabannavar
Isabel Zaror
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34577667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1694360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1694360T3 publication Critical patent/DK1694360T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK04810420.2T 2003-11-04 2004-11-04 Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning DK1694360T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51733703P 2003-11-04 2003-11-04
US52557903P 2003-11-26 2003-11-26
US56571004P 2004-04-27 2004-04-27
PCT/US2004/036957 WO2005044306A2 (en) 2003-11-04 2004-11-04 Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection

Publications (1)

Publication Number Publication Date
DK1694360T3 true DK1694360T3 (da) 2010-10-18

Family

ID=34577667

Family Applications (4)

Application Number Title Priority Date Filing Date
DK04810420.2T DK1694360T3 (da) 2003-11-04 2004-11-04 Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning
DK04810510T DK1682180T3 (da) 2003-11-04 2004-11-04 Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf
DK04810421.0T DK1682178T3 (da) 2003-11-04 2004-11-04 Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
DK09075395.5T DK2149585T3 (da) 2003-11-04 2004-11-04 Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK04810510T DK1682180T3 (da) 2003-11-04 2004-11-04 Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf
DK04810421.0T DK1682178T3 (da) 2003-11-04 2004-11-04 Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
DK09075395.5T DK2149585T3 (da) 2003-11-04 2004-11-04 Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer

Country Status (23)

Country Link
EP (6) EP2149585B1 (da)
JP (6) JP5019881B2 (da)
KR (2) KR101125127B1 (da)
CN (2) CN1938045B (da)
AT (3) ATE447412T1 (da)
AU (3) AU2004287482B2 (da)
CA (3) CA2544853C (da)
CY (3) CY1110231T1 (da)
DE (3) DE602004028037D1 (da)
DK (4) DK1694360T3 (da)
EC (2) ECSP066607A (da)
ES (3) ES2333971T3 (da)
HK (4) HK1095270A1 (da)
HR (2) HRP20100066T1 (da)
IL (1) IL175225A (da)
MA (1) MA28331A1 (da)
PL (4) PL2149585T3 (da)
PT (4) PT1694360E (da)
RS (2) RS51230B (da)
SG (1) SG148143A1 (da)
SI (3) SI1682180T1 (da)
WO (3) WO2005044306A2 (da)
ZA (1) ZA200604419B (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1684869B1 (en) * 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
SI1682180T1 (sl) * 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
WO2005108428A2 (en) * 2004-02-26 2005-11-17 Compugen Ltd. Cd40 splice variants and their uses
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
DK1889065T3 (da) * 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
CN101325970B (zh) * 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
DK1954718T3 (da) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer,
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
AU2006323315B2 (en) 2005-12-09 2014-02-20 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US8945564B2 (en) * 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
MX2009013886A (es) 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
WO2009062125A1 (en) * 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
RU2491095C2 (ru) * 2007-11-09 2013-08-27 Новартис Аг Применения анти-cd40-антител
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2010236168B2 (en) 2009-04-18 2015-08-13 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
DK2454283T3 (da) 2009-07-15 2018-05-07 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af antistoffer med høj affinitet
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EA030436B1 (ru) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх АНТИТЕЛА К IL-23p19 ИЛИ ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ, ИХ ПРИМЕНЕНИЕ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ АНТИТЕЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ВЫДЕЛЕННЫЕ ПОЛИНУКЛЕОТИДЫ, ЭКСПРЕССИОННЫЕ ВЕКТОРЫ И КЛЕТКИ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2016201742B2 (en) * 2010-11-15 2017-11-02 Novartis Ag Silent Fc variants of anti-CD40 antibodies
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PL2646466T3 (pl) * 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
EP2676677B1 (en) * 2011-02-17 2019-05-22 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-cd40 antibody pharmaceutical preparation
EP2682462B1 (en) * 2011-02-28 2017-11-08 Napajen Pharma, Inc. (nucleic acid)-polysaccharide complex
EP4338750A2 (en) 2011-03-11 2024-03-20 Beth Israel Deaconess Medical Center Inc. Anti-cd40 antibodies and uses thereof
ES2664619T3 (es) * 2011-04-21 2018-04-20 Bristol-Myers Squibb Company Polipéptidos de anticuerpos que antagonizan CD40
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
CN104105707B (zh) 2011-11-17 2020-03-06 G·容 医疗用途的双特异性抗体
EP3326649B1 (en) * 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CA2888763A1 (en) * 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014076292A1 (en) 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
WO2014200349A1 (en) * 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
CN108025068A (zh) * 2014-03-12 2018-05-11 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2943177A1 (en) * 2014-03-19 2015-09-24 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40l
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
ES2887549T3 (es) 2014-09-03 2021-12-23 Boehringer Ingelheim Int Compuesto dirigido a IL-23A y TNF-alfa y usos del mismo
CA2969847A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
AU2016270640B2 (en) 2015-05-29 2022-03-10 Abbvie Inc. Anti-CD40 antibodies and uses thereof
SI3334747T1 (sl) 2015-08-13 2024-02-29 Amgen Inc. Globinsko nabito filtriranje proteinov, ki vežejo antigen
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
EP3355921A4 (en) * 2015-09-30 2019-05-22 Janssen Biotech, Inc. ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE
SG10201913248VA (en) 2016-04-18 2020-02-27 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
KR102198998B1 (ko) * 2017-06-01 2021-01-07 서울대학교 산학협력단 신규한 항-ｃｄ40 항체 및 이의 용도
CA3064298A1 (en) * 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
KR20200044016A (ko) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7445977B2 (ja) * 2018-01-29 2024-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ２媒介性疾患及び障害の治療法
JP2021513367A (ja) * 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
CN117229396A (zh) * 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US4738927A (en) 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
BE893016R (fr) 1982-04-29 1982-08-16 Amatucci Aldo Turbine a vent
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US5700913A (en) 1982-12-15 1997-12-23 Ajinomoto Co., Inc. Unglycosylated human interleukin-2 polypeptides
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4745180A (en) 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4931543A (en) 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991004282A1 (en) 1989-09-21 1991-04-04 Idemitsu Kosan Co., Ltd. Arylstyrene polymer and copolymer and process for preparing the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
WO1995023512A1 (en) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
EP1034001B1 (en) 1997-06-20 2004-08-04 Biogen Idec MA Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6566500B1 (en) 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
CA2369820A1 (en) 1999-04-16 2000-10-26 Frank Dicker Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
HU0800692D0 (en) 1999-10-04 2009-01-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005510570A (ja) * 2001-11-26 2005-04-21 カイロン コーポレイション 多発性硬化症処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体療法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1682180T1 (sl) * 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
CN1929862B (zh) * 2003-11-04 2012-02-15 诺华疫苗和诊断公司 拮抗性抗-cd40单克隆抗体治疗慢性淋巴细胞性白血病的应用
EP1684869B1 (en) * 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
ATE474599T1 (de) * 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
DE602004028643D1 (de) * 2003-11-04 2010-09-23 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
JP6039343B2 (ja) 2012-10-04 2016-12-07 キヤノン株式会社 電子機器、電子機器の制御方法、プログラム、記憶媒体

Also Published As

Publication number Publication date
RS53073B (en) 2014-04-30
AU2011201529A1 (en) 2011-04-28
JP2007512243A (ja) 2007-05-17
KR20060132602A (ko) 2006-12-21
DK1682180T3 (da) 2010-01-11
SI1682180T1 (sl) 2010-03-31
AU2004287879C1 (en) 2011-05-26
CA2544853C (en) 2014-05-20
RS51230B (sr) 2010-12-31
ATE476448T1 (de) 2010-08-15
HK1095270A1 (en) 2007-05-04
ECSP066607A (es) 2006-10-25
CN1905897A (zh) 2007-01-31
DE602004028505D1 (de) 2010-09-16
CN1905897B (zh) 2012-09-05
ATE473016T1 (de) 2010-07-15
WO2005044854A3 (en) 2005-08-11
AU2004287879B2 (en) 2011-01-06
PT1694360E (pt) 2010-12-13
JP2007510666A (ja) 2007-04-26
CY1110231T1 (el) 2015-01-14
ZA200604419B (en) 2008-06-25
CA2544949A1 (en) 2005-05-19
EP1682180B1 (en) 2009-11-04
CY1110803T1 (el) 2015-06-10
HK1139964A1 (en) 2010-09-30
ES2333971T3 (es) 2010-03-03
PL1682180T3 (pl) 2010-04-30
EP2248830A1 (en) 2010-11-10
AU2011201529B2 (en) 2012-11-01
KR20060111555A (ko) 2006-10-27
PT2149585E (pt) 2013-11-27
AU2004287482A1 (en) 2005-05-19
CA2544948A1 (en) 2005-05-19
HK1095091A1 (en) 2007-04-27
EP1682178B1 (en) 2010-07-07
CA2544853A1 (en) 2005-05-19
PL2149585T3 (pl) 2014-01-31
PT1682180E (pt) 2010-02-10
MA28331A1 (fr) 2006-12-01
JP2008502309A (ja) 2008-01-31
CN1938045A (zh) 2007-03-28
KR101403910B1 (ko) 2014-06-09
EP1682178A2 (en) 2006-07-26
EP2149585B1 (en) 2013-08-14
AU2004287482B2 (en) 2011-04-14
CA2544949C (en) 2014-02-25
WO2005044854A2 (en) 2005-05-19
EP1694360A2 (en) 2006-08-30
WO2005044294A2 (en) 2005-05-19
ES2435410T3 (es) 2013-12-19
EP1682180A2 (en) 2006-07-26
DK1682178T3 (da) 2010-10-04
JP2011072317A (ja) 2011-04-14
KR101125127B1 (ko) 2012-03-16
EP1682178B8 (en) 2010-09-01
JP2011126900A (ja) 2011-06-30
SG148143A1 (en) 2008-12-31
DE602004028037D1 (de) 2010-08-19
PT1682178E (pt) 2010-10-21
WO2005044306A2 (en) 2005-05-19
HRP20131085T1 (hr) 2013-12-20
DK2149585T3 (da) 2013-10-21
JP4765039B2 (ja) 2011-09-07
JP2011105769A (ja) 2011-06-02
DE602004023961D1 (de) 2009-12-17
ES2346977T3 (es) 2010-10-22
JP4746552B2 (ja) 2011-08-10
AU2004287879A1 (en) 2005-05-19
SI1682178T1 (sl) 2010-11-30
CN1938045B (zh) 2014-03-26
HRP20100066T1 (hr) 2010-03-31
WO2005044294A3 (en) 2005-09-15
PL1694360T3 (pl) 2011-04-29
HK1094156A1 (en) 2007-03-23
EP2255828A1 (en) 2010-12-01
EP1694360B1 (en) 2010-08-04
PL1682178T3 (pl) 2010-12-31
CY1110839T1 (el) 2015-06-10
ECSP12006607A (es) 2012-04-30
WO2005044306A3 (en) 2005-09-15
IL175225A (en) 2011-12-29
JP5019881B2 (ja) 2012-09-05
ATE447412T1 (de) 2009-11-15
EP2149585A1 (en) 2010-02-03
IL175225A0 (en) 2006-09-05
SI1694360T1 (sl) 2010-12-31

Similar Documents

Publication Publication Date Title
DK1694360T3 (da) Anvendelse af antagonist anti-CD40-antistoffer til behandling af autoimmune og inflammatoriske sygdomme og organtransplantationafstødning
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
CY1111011T1 (el) Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1110874T1 (el) Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
EA200301097A1 (ru) Иммунотерапевтические комбинации для лечения опухолей, которые сверхэкспрессируют ганглиозиды
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
CY1114654T1 (el) Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων